The cachexia definition used in clinical practice came out of a consensus conference in 2008, and it turns on one distinction: this is muscle loss driven by an underlying illness, not by a shortage of food.
Key takeaways
- The 2008 consensus wording is that cachexia is a complex metabolic syndrome associated with underlying illness and characterised by loss of muscle with or without loss of fat mass.
- The prominent clinical feature in adults is weight loss corrected for fluid retention. The correction matters, because oedema can mask it entirely.
- Cancer cachexia carries explicit numbers: weight loss above 5%, or above 2% when body mass index is already under 20, or above 2% in someone who already meets sarcopenia criteria.
- The definition rules out starvation, age-related muscle loss, primary depression, malabsorption and hyperthyroidism. Those are different problems with different answers.
- What separates cachexia from ordinary undernutrition is that conventional nutritional support does not fully reverse it.
The cachexia definition agreed by consensus
A group of clinicians and researchers met in Washington DC to settle a question that had been open for decades: what does the word actually mean. Their report, published in Clinical Nutrition in 2008, gave the wording most later work builds on. Cachexia is a complex metabolic syndrome associated with underlying illness and characterised by loss of muscle with or without loss of fat mass.
Every clause in that sentence is doing work.
Complex metabolic syndrome. Not a symptom, and not a single measurement. The 2008 group listed anorexia, inflammation, insulin resistance and increased muscle protein breakdown as frequently associated features.
Associated with underlying illness. Cachexia is downstream of something else, which is why the coding system treats it the way it does.
Loss of muscle with or without loss of fat mass. Muscle is the required element. Fat may or may not go with it, which is one reason a normal body weight is not reassurance.
The report also named the prominent clinical feature: weight loss in adults, corrected for fluid retention, or growth failure in children once endocrine causes are excluded. That correction for fluid is not a technicality. In heart failure, liver disease and advanced cancer, fluid can accumulate fast enough to hold the number on the scale steady while lean tissue disappears underneath it.
What the cachexia definition deliberately excludes
The 2008 statement is unusually direct about what cachexia is not. It is distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption and hyperthyroidism. Those exclusions are the practical half of the definition, because each excluded condition has a different answer.
| Cachexia | Simple undernutrition | Sarcopenia | |
|---|---|---|---|
| Primary driver | An underlying illness and the metabolic response to it | Insufficient energy and protein intake | Ageing, with disuse and chronic disease as contributors |
| Fat mass | Lost in some patients, preserved in others | Preferentially mobilised early | Not part of the definition, often normal or increased |
| Inflammation | Frequently present | Not a defining feature | Not a defining feature |
| Response to feeding | Not fully reversed by conventional nutritional support | Reverses with adequate refeeding | Responds to resistance training plus adequate protein, not to feeding alone |
| ICD-10-CM code | R64, or E88.A when the underlying condition is documented | E41 for nutritional marasmus | M62.84 |
The sarcopenia line gets blurred most often, because both conditions end in less muscle and a weaker patient. The sarcopenia definition is built around ageing and measurable thresholds for muscle mass, strength and physical performance. Cachexia is built around illness and a metabolic state. A person can have both, but calling one by the other's name changes what gets treated.
The diagnostic thresholds for cancer cachexia
The 2008 definition describes a syndrome. It does not tell a clinician where the line sits. For cancer, an international expert panel closed that gap in 2011 with a framework published in Lancet Oncology, and its numbers are the ones most widely used.
That panel defined cancer cachexia as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass, with or without loss of fat mass, that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. The agreed diagnostic criterion is any one of the following:
- Weight loss greater than 5%
- Weight loss greater than 2% in someone whose body mass index is already below 20
- Weight loss greater than 2% in someone who already meets criteria for sarcopenia
The second and third thresholds are the interesting ones. They exist because 3% lost from a depleted person is not the same event as 3% lost from someone with reserves. A single universal percentage would under-diagnose the patients in most trouble.
The framework describes the pathophysiology as a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism.
Precachexia, cachexia and refractory cachexia
The 2011 framework added something the 2008 wording did not have: stages. Cachexia develops progressively through precachexia, cachexia and refractory cachexia.
Precachexia describes early metabolic change and modest weight loss before the thresholds are met. It is the stage where intervention has the best theoretical chance, and the stage most likely to be missed.
Cachexia is the point at which the criteria above are satisfied.
Refractory cachexia describes advanced disease where the wasting is no longer responsive and the clinical focus shifts. Naming this stage was deliberate: it gives teams a way to say that aggressive nutritional intervention has stopped being the right goal.
Severity is graded by combining how depleted the energy stores and body protein already are, read from body mass index, with how fast weight is still coming off. The panel also set out the assessment domains: reduced food intake, catabolic drive, muscle mass and strength, and functional and psychosocial impairment. That last one is a reminder that the syndrome is measured partly in what a person can still do.
Where cachexia is recognised
Cancer has the most developed criteria, but the syndrome was never cancer-only. The 2008 panel was assembled across specialties precisely because the same picture appears in chronic heart failure, chronic obstructive pulmonary disease, chronic kidney disease and HIV/AIDS.
Cardiac cachexia has its own weight-loss threshold and prognostic data. Wasting in kidney disease is covered in myostatin and chronic kidney disease. What travels across all of them is the core idea: an illness changes metabolism, and muscle is what pays for it.
How the definition becomes a diagnosis code
Because cachexia sits downstream of another illness, ICD-10-CM splits it in two. R64 covers cachexia recorded without a documented underlying cause. E88.A, wasting disease due to underlying condition, covers cachexia attributed to a named illness and instructs the coder to sequence that illness first. The two carry an Excludes1 relationship, meaning they are never reported together. Our cachexia ICD-10 guide works through the documentation that decides which applies.
Why eating more does not close the gap
This is the part families find hardest, and it is worth stating plainly.
In simple undernutrition, the body is short of fuel and responds to being given fuel. In cachexia, the body is running a catabolic program driven by the underlying disease. Muscle protein breakdown is elevated, insulin resistance blunts the anabolic response to feeding, and appetite is often suppressed at the same time. Calories arriving into that system do not partition the way they would in a healthy person.
Both consensus documents encode this. The 2011 framework builds "cannot be fully reversed by conventional nutritional support" directly into the definition. Nutritional care still matters, and no one running a cachexia clinic stops feeding patients. But nutrition is supportive care here rather than a cure, and a family told otherwise ends up blaming themselves for something the biology decided.
Where myostatin fits into the cachexia definition
If feeding cannot fully reverse muscle loss, the obvious question is whether the signal driving the loss can be interrupted instead.
Myostatin, also known as GDF-8, is a TGF-beta family protein that acts as a brake on skeletal muscle growth. It signals with the related ligand activin A through the activin type IIB receptor, and that axis has been the main pharmacological target explored in muscle-wasting states. The theory is straightforward: if the disease is pushing a growth-suppressing signal, block the signal.
The practice has been harder. No myostatin-pathway drug is approved for cachexia in any market, and the trial history in wasting conditions mixes lean-mass gains with disappointing functional endpoints. We cover that record in myostatin and cancer cachexia. The definition is settled; the treatment is not.
Sources
- Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clinical Nutrition. 2008;27(6):793-799.
- Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology. 2011;12(5):489-495.
- ICD-10-CM code R64, Cachexia, AAPC Codify.
- ICD-10-CM code E88.A, Wasting disease (syndrome) due to underlying condition, AAPC Codify.
Frequently asked questions
What is the simplest accurate cachexia definition?
Cachexia is muscle loss caused by an underlying illness and the metabolic response to it, which conventional nutritional support cannot fully reverse. Fat may be lost alongside the muscle or preserved. The 2008 consensus wording: a complex metabolic syndrome associated with underlying illness and characterised by loss of muscle with or without loss of fat mass.
How much weight loss counts as cachexia?
In cancer, the 2011 consensus set the threshold at weight loss above 5%, or above 2% if body mass index is already below 20, or above 2% in someone meeting sarcopenia criteria. Other conditions use their own figures: cardiac cachexia is conventionally defined by non-oedematous weight loss of at least 6% over the previous 6 to 12 months.
Is cachexia the same as sarcopenia?
No, and the 2008 consensus separates them explicitly. Sarcopenia is age-related loss of muscle mass, strength and physical performance, with defined measurement thresholds. Cachexia is illness-driven and metabolic. They can occur together, and the cancer cachexia criteria use sarcopenia as one trigger for a lower weight-loss threshold, but they are distinct diagnoses with distinct codes.
Can someone have cachexia without losing weight on the scale?
The scale can hide it. The consensus definition specifies weight loss corrected for fluid retention, because oedema and ascites offset lost lean tissue, and muscle loss with preserved fat mass can keep total weight stable. Body composition and functional measures matter alongside weight.
Is there an approved drug for cachexia?
No drug is approved specifically to reverse cachexia as the consensus documents define it, and the myostatin and activin pathway programmes tested in wasting conditions have produced mixed results. Management centres on treating the underlying illness, supportive nutrition, symptom control and activity where feasible. Treatment decisions belong with the clinical team.
This article is for educational purposes only and is not medical advice. Cachexia is a clinical diagnosis that requires assessment by a qualified healthcare professional, and unexplained weight loss should always be investigated. Nothing here should be used to start, stop or change any treatment.